Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management

Jahansouz, Cyrus; Xu, Hong‐Liang; Kizy, Scott; Thomas, Avis J.; Josephrajan, Ajeetha; Hertzel, Ann V.; Foncea, Rocı́o; Connett, John C.; Billington, Charles J.; Jensen, Michael D.; Körner, Judith; Bernlohr, David A.; Ikramuddin, Sayeed

doi:10.1016/j.surg.2018.08.007

Cited by 7 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Fabp4mentioning

confidence: 99%

“…In humans, serum levels of FABP4 are higher in obese, type 1 diabetic, type 2 diabetic and gestational diabetic individuals compared to non-obese, non-diabetic subjects [ 34 , 35 , 36 , 37 ]. Gastric bypass surgery reduces circulating FABP4 by 42% in obese patients with type 2 diabetes, whereas behavioral and nutritional intervention alone does not reduce the serum levels of FABP4 [ 35 ]. Cohort studies including obese or diabetic patients with their family revealed that FABP4 levels were high with first-degree relatives of type 1 diabetic patients [ 37 ] and in children of obese parents, even if they were not obese themselves [ 38 ].…”

Section: Fabp4mentioning

confidence: 99%

See 1 more Smart Citation

Adipose-Derived Lipid-Binding Proteins: The Good, the Bad and the Metabolic Diseases

Frances

Tavernier

Viguerie

2021

IJMS

View full text Add to dashboard Cite

Adipose tissue releases a large range of bioactive factors called adipokines, many of which are involved in inflammation, glucose homeostasis and lipid metabolism. Under pathological conditions such as obesity, most of the adipokines are upregulated and considered as deleterious, due to their pro-inflammatory, pro-atherosclerotic or pro-diabetic properties, while only a few are downregulated and would be designated as beneficial adipokines, thanks to their counteracting properties against the onset of comorbidities. This review focuses on six adipose-derived lipid-binding proteins that have emerged as key factors in the development of obesity and diabetes: Retinol binding protein 4 (RBP4), Fatty acid binding protein 4 (FABP4), Apolipoprotein D (APOD), Lipocalin-2 (LCN2), Lipocalin-14 (LCN14) and Apolipoprotein M (APOM). These proteins share structural homology and capacity to bind small hydrophobic molecules but display opposite effects on glucose and lipid metabolism. RBP4 and FABP4 are positively associated with metabolic syndrome, while APOD and LCN2 are ubiquitously expressed proteins with deleterious or beneficial effects, depending on their anatomical site of expression. LCN14 and APOM have been recently identified as adipokines associated with healthy metabolism. Recent findings on these lipid-binding proteins exhibiting detrimental or protective roles in human and murine metabolism and their involvement in metabolic diseases are also discussed.

show abstract